Overview

• U.S. District Judge Matthew Kacsmaryk declined to dismiss the mifepristone lawsuit and moved it to the Eastern District of Missouri.
• The shift keeps alive a path to a merits ruling that could reinstate earlier restrictions or affect approvals, though no decision on the substance has been made.
• Idaho, Kansas and Missouri were allowed to intervene after private plaintiffs lost at the Supreme Court last year for lack of standing.
• The states seek to cut eligibility from 10 weeks to seven, require three in‑person visits, limit mail and telehealth dispensing, and challenge approval of generics.
• GenBioPro joined as a defendant and criticized the case as politically motivated, while the FDA maintains mifepristone’s safety and HHS has initiated a review of safety regulations.